Questions to Ask a Provider
A checklist for evaluating a supervised ketamine program. It is a tool for asking better questions — not a rating, a ranking, or a recommendation of any provider.
Everything in this section describes ketamine therapy as it happens under clinical supervision.
It is not a guide to using ketamine on your own. Screening, medication review, dosing, and eligibility are clinical decisions made by a provider who knows your history. Nothing here replaces that conversation.
If you need help right now
- United States: Call or text 988 (Suicide & Crisis Lifeline), available 24/7.
- Outside the US: Contact your local emergency number, or find a helpline via findahelpline.com.
- If you are in immediate danger, go to your nearest emergency department.
What this is and is not
This page is educational. It does not name, rank, score, endorse, or refer providers, it does not recommend treatment packages or quote prices, and it contains no dosing information. It is not medical advice and it cannot tell you whether a specific program is right for you. Use it to prepare for a conversation with clinicians, and make decisions with a qualified clinician who knows your history.
Why the questions matter
Ketamine is an FDA-approved anesthetic. Its use for depression and other psychiatric indications is largely off-label, which means the treatment itself is legal for a clinician to provide but is not governed by a single federal standard covering how programs must screen, monitor, staff, or follow up. Those requirements come instead from state medical and nursing boards, facility licensing rules, and professional-society guidance, which differ from state to state.
Well-established· Ketamine is FDA-approved as an anesthetic; the FDA states it has not approved ketamine for any psychiatric disorder (FDA safety communication, October 10, 2023) — Supported by replicated, well-conducted research.
One area where a federal position does exist is compounded ketamine. In an October 10, 2023 safety communication, the FDA warned patients and clinicians about risks associated with compounded ketamine products, including oral formulations used at home without monitoring, noting that compounded products are not FDA-evaluated for safety or effectiveness. A February 2022 alert had raised related concerns.
Well-established· FDA safety communication, October 10, 2023 — risks of compounded ketamine products for psychiatric disorders — Supported by replicated, well-conducted research.
We describe this as regulatory fragmentation rather than an absence of regulation. Programs operate under real licensing and prescribing law; what varies is the specific operational standard applied to a supervised session, and no single public source tracks that variation comprehensively.
Source pending verification: a comprehensive, current, state-by-state comparison of operational requirements for ketamine treatment programs
Related resources
Two existing Ketalux pages cover neighbouring ground and are not duplicated here. The safety-focused provider questions page concentrates on clinical safety protocols, and warning signs when evaluating a provider covers the patterns that should prompt more scrutiny. Read them alongside this checklist.
The checklist
Tick boxes as you go, or print the page and use it on paper. Nothing you tick is saved.
Credentials and clinical oversight
Who is responsible for the medical decisions, and what is their training and licensure?
Screening and eligibility
What is assessed before anyone is accepted for treatment?
Monitoring during the session
What is measured, by whom, and how often?
Emergency preparedness
What happens when something goes wrong?
Consent, records, and privacy
What are you agreeing to, and what happens to your information?
After the session and continuity of care
What happens between and after appointments?
Cost and commercial structure
Understanding how a program is paid is part of understanding its incentives. Ask for the specifics in writing rather than relying on a figure quoted anywhere online.
Privacy
Checkbox selections exist only in the browser's memory for as long as this page is open. They are not written to local storage, a database, or an account, they are not sent to analytics, and they are gone when you reload or close the tab.
Independent publisher and editor of Ketalux, based in Chicago, Illinois. Ira commissions, edits, and reviews every article on the site, and is not a licensed clinician. Contact: ira@idigits.com.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.